Edgestream Partners L.P. Acquires 55,516 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR

Edgestream Partners L.P. lifted its holdings in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 152.2% in the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 91,997 shares of the biotechnology company’s stock after buying an additional 55,516 shares during the period. Edgestream Partners L.P.’s holdings in Arrowhead Pharmaceuticals were worth $5,768,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also modified their holdings of the business. Tsfg LLC bought a new position in Arrowhead Pharmaceuticals in the 4th quarter valued at approximately $25,000. iSAM Funds UK Ltd bought a new stake in shares of Arrowhead Pharmaceuticals during the third quarter worth $29,000. First Horizon Corp bought a new stake in shares of Arrowhead Pharmaceuticals during the fourth quarter worth $32,000. WPG Advisers LLC increased its holdings in shares of Arrowhead Pharmaceuticals by 384.8% during the fourth quarter. WPG Advisers LLC now owns 543 shares of the biotechnology company’s stock worth $36,000 after buying an additional 431 shares in the last quarter. Finally, Hantz Financial Services Inc. increased its holdings in shares of Arrowhead Pharmaceuticals by 177.1% during the fourth quarter. Hantz Financial Services Inc. now owns 737 shares of the biotechnology company’s stock worth $49,000 after buying an additional 471 shares in the last quarter. 62.61% of the stock is currently owned by institutional investors.

Key Arrowhead Pharmaceuticals News

Here are the key news stories impacting Arrowhead Pharmaceuticals this week:

• Positive Sentiment: B. Riley raises target to $123: B. Riley Financial lifted its price target from $101 to $123 and initiated or reiterated a Buy rating. The new target represents approximately 40.9% upside from the referenced share price, signaling increased confidence in Arrowhead’s pipeline and future commercial potential. Benzinga article
• Positive Sentiment: Upcoming cardiometabolic milestones strengthen the bull case: A report highlights the potential impact of dual Phase 3 milestones involving Arrowhead’s RNAi cardiometabolic programs. Successful clinical progress could materially improve the company’s long-term growth outlook and serve as a catalyst for the stock. The Bull Case For Arrowhead Pharmaceuticals Could Change Following Dual Phase 3 RNAi Cardiometabolic Milestones
• Positive Sentiment: HC Wainwright raises long-term earnings forecasts: HC Wainwright increased its EPS projections for fiscal 2027 through 2030, including a reduction in the expected 2029 loss to $0.80 per share from $1.09 and a forecast of $4.64 EPS in 2030 versus $3.06 previously. The firm maintains a Buy rating and a $115 price target, reflecting expectations for improving profitability as Arrowhead’s programs advance. HC Wainwright Has Bullish Estimate for ARWR Q4 Earnings
• Positive Sentiment: Analyst price-target upgrade: HC Wainwright separately boosted its Arrowhead price target to $115 from its prior target, maintaining its Buy recommendation. HC Wainwright Boosts Arrowhead Pharmaceuticals Price Target to $115

Insider Transactions at Arrowhead Pharmaceuticals

In related news, Director Hongbo Lu sold 2,970 shares of the business’s stock in a transaction on Tuesday, May 12th. The shares were sold at an average price of $76.88, for a total value of $228,333.60. Following the transaction, the director owned 52,012 shares in the company, valued at $3,998,682.56. The trade was a 5.40% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 3.60% of the stock is currently owned by insiders.

Arrowhead Pharmaceuticals Stock Up 1.3%

Arrowhead Pharmaceuticals stock opened at $87.32 on Friday. The firm has a market cap of $12.30 billion, a price-to-earnings ratio of -40.61 and a beta of 1.26. Arrowhead Pharmaceuticals, Inc. has a 52-week low of $15.01 and a 52-week high of $95.49. The company has a debt-to-equity ratio of 1.41, a quick ratio of 6.23 and a current ratio of 6.23. The firm has a 50 day moving average price of $78.84 and a two-hundred day moving average price of $70.57.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last posted its quarterly earnings data on Thursday, May 7th. The biotechnology company reported ($0.93) EPS for the quarter, beating analysts’ consensus estimates of ($1.10) by $0.17. Arrowhead Pharmaceuticals had a negative net margin of 48.38% and a negative return on equity of 55.09%. The company had revenue of $73.74 million for the quarter, compared to analyst estimates of $73.84 million. During the same period in the prior year, the firm posted $2.75 EPS. The company’s quarterly revenue was down 86.4% on a year-over-year basis. Equities analysts predict that Arrowhead Pharmaceuticals, Inc. will post -3.08 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the company. Leerink Partners raised their price objective on Arrowhead Pharmaceuticals from $61.00 to $72.00 and gave the company a “market perform” rating in a report on Wednesday, June 17th. Sanford C. Bernstein upped their target price on Arrowhead Pharmaceuticals from $35.00 to $46.00 and gave the stock a “market perform” rating in a report on Wednesday, May 13th. HC Wainwright increased their target price on Arrowhead Pharmaceuticals from $100.00 to $115.00 and gave the company a “buy” rating in a research report on Monday. Royal Bank Of Canada lifted their price target on Arrowhead Pharmaceuticals from $80.00 to $87.00 and gave the company an “outperform” rating in a research note on Friday, May 8th. Finally, Stifel Nicolaus started coverage on Arrowhead Pharmaceuticals in a report on Tuesday, July 14th. They set a “buy” rating and a $98.00 price target on the stock. Nine research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Arrowhead Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $96.92.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.